The DOI matches its Crossref record.
Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT)
Open accessAbstract
Objective To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness. Design Prospective, double blind, randomised, placebo controlled trial. Setting Approach to Mount Everest base camp in the Nepal Himalayas at 4280 m or 4358 m and study end point at 4928 m during October and November 2002. Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent. Main outcome measures Incidence measured by Lake Louise acute mountain sickness score ≥ 3 with headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores ≥ 5), incidence of headache, and severity of headache. Results Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34% for placebo, 12% for acetazolamide (odds ratio 3.76, 95% confidence interval 1.91 to 7.39, number needed to treat 4), 35% for ginkgo (0.95, 0.56 to 1.62), and 14% for combined ginkgo and acetazolamide (3.04, 1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18% for placebo, 3% for acetazoalmide (6.46, 2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1, 0.52 to 1.90), and 7% for combined ginkgo and acetazolamide (2.95, 1.30 to 6.70). Conclusions When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The cerebral effects of ascent to high altitudes
Wilson, M. H., Newman, S., & Imray, C. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70014-6 · Cited by 525
The Physiologic Basis of High-Altitude Diseases
West, J. B. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00010 · Cited by 365
Acute Mountain Sickness: Pathophysiology, Prevention, and Treatment
Imray, C., Wright, A., Subudhi, A., & Roach, R. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.02.003 · Cited by 318
The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America
Hill, D. R., Ericsson, C. D., Pearson, R. D., Keystone, J. S., Freedman, D. O., Kozarsky, P. E., DuPont, H. L., Bia, F. J., Fischer, P. R., & Ryan, E. T. (2006) · Clinical Infectious Diseases · doi:10.1086/508782 · Cited by 296
Luks, A. M., McIntosh, S. E., Grissom, C. K., Auerbach, P. S., Rodway, G. W., Schoene, R. B., Zafren, K., & Hackett, P. H. (2010) · Wilderness & Environmental Medicine · doi:10.1016/j.wem.2010.03.002 · Cited by 274
Metadata
- Authors
- Gertsch, J. H., Basnyat, B., Johnson, E. W., Onopa, J., & Holck, P. S.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2004-03-11
- Volume
- 328
- Issue
- 7443
- Pages
- 797
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2154994878
- Cited by
- 158
- References
- 0
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). https://app.cochat.ai/papers/10.1136/bmj.38043.501690.7c
- The paper
- Gertsch, J. H., Basnyat, B., Johnson, E. W., Onopa, J., & Holck, P. S. (2004). Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. https://doi.org/10.1136/bmj.38043.501690.7c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.